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Danshen is a traditional Chinese medicine with many bene�cial eﬀects on cardiovascular diseases. e aim of this study was to
evaluate the mechanisms responsible for the antiatherogenic eﬀect of water soluble Danshen extracts (DEs). Rat vascular smooth
muscle cells (VSMCs) and human umbilical vein endothelial cells (HUVECs) were treated with DE. To evaluate the eﬀects of DE in
vivo, carotid balloon injury and tail vein thrombosis were induced in Sprague-Dawley (SD) rats and iliac artery stent was induced
in New �ealand white rabbits.e inhibitory action of DE on platelet aggregation was con�rmed with an impedance aggregometer.
DE inhibited the production of reactive oxygen species, and the migration and proliferation of platelet-derived growth factor-BB
stimulated VSMCs. Furthermore, DE prevented in�ammation and apoptosis in HUVECs. Both eﬀects of DE were recon�rmed
in both rat models. DE treatment attenuated platelet aggregation in both in vivo and ex vivo conditions. Pretreatment with DE
prevented tail vein thrombosis, which is normally induced by 𝜅𝜅-carrageenan injection. Lastly, DE-treated rabbits showed decreased
in-stent restenosis of stented iliac arteries.ese results suggest that water soluble DEmodulates key atherogenic events in VSMCs,
endothelial cells, and platelets in both in vitro and in vivo conditions.
1. Introduction
Danshen (Salviamiltiorrhiza) has been used for the treatment
of cardiovascular and cerebrovascular diseases [1, 2]. Speci�c
clinical uses include angina pectoris, hypercholesterolemia,
and acute ischemic stroke. is traditional medicine is a
popular drug in China, where it is used either on its own
or mixed with other herbs [3]. Even in the United States,
Danshen has been widely used in recent years [4, 5]. Speci�-
cally, the FufangDanshenDripping Pill has clearedAmerican
Phase II clinical trials in patients with chronic stable angina
pectoris (http://clinicaltrials.gov/, no. NCT00797953). e
bene�cial eﬀects of Danshen on cardiovascular diseases arise
from its ability to prevent atherosclerosis. Danshen, as a
therapeutic agent for cardiovascular diseases, contributes
to improved microcirculation, vasodilation, anticoagulation,
and anti-in�ammation [6, 7]. In addition to its eﬀects on car-
diovascular diseases, some studies have shown that Danshen
may be useful in a diverse range of diseases including liver
�brosis, chronic renal failure, and acute pancreatitis [2].
Recently, several chemical compounds belonging to two
speci�c classes were isolated from Danshen; caﬀeic acid-
derived phenolic acids and tanshinones belonging to the
diterpene quinine family [8]. According to the solubility,
these compounds could be simply classi�ed as either water-
soluble agents or lipid-soluble agents. Most studies have
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reported that the lipid-soluble components of Danshen
extracts (DE), such as tanshinone IIA, have speci�c eﬀects on
cardiovascular disease [9].
Although the bene�cial eﬀects of Danshen on cardio-
vascular diseases have been reported in other studies, the
underlying mechanisms of DE as well as the role of its water-
soluble compounds have not yet been evaluated.With respect
to the pharmacological and therapeutic pro�les of Danshen
in the vascular system, the aim of the present study was
to evaluate the mechanisms involved in the antiatherogenic
eﬀects of DE, which contains an abundance of water-soluble
compounds.
2. Materials andMethods
is study conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
ofHealth (NIHPublication, 8th Edition, 2011). Furthermore,
approval was granted by the Institutional Animal Care and
Use Committee of Yonsei University Health System (permit
number 2010-0187). All animal studies were performed in
facilities approved by the Association for Assessment and
Accreditation of Laboratory Animal Care. In all animal
models, animals were anesthetized with an intraperitoneal
injection of Ketamine-Xylazine (100mg : 10mg per kg of
body weight) once every procedure. e adequacy of anes-
thesia in Sprague-Dawley (SD) was assessed by absence
of re�exes prior to rapid cervical dislocation, and that in
New �ealand white rabbits was con�rmed by monitoring
respiratory rate and ECG.
2.1. Production of Danshen Extracts. Dried and powdered
roots of Salvia miltiorrhiza (200 g) were boiled with water
(1600mL) for 2 hours. e extracted solution was then
�ltered and solid deposits were removed. e extracted
solution was then concentrated by heating with a rotary
evaporator. Next, identical volumes of extracted solution
and butanol were mixed in a separatory funnel. e upper
solution of the mixture was then collected and concen-
trated with a rotary evaporator. e components of the
collected DE were evaluated via ultra performance liquid
chromatography-ultraviolet (UPLC-UV). Powdered DE was
dissolved in distilled water containing 1% dimethyl sulfoxide
(DMSO) (Sigma-Aldrich Co., MO, USA) and diluted to �nal
experimental concentrations.
2.2. Primary Cell Isolation and Culture. Rat vascular smooth
muscle cells (VSMCs) were isolated from the thoracic aorta
of SD rats weighing between 200 to 250 g (Orient-Charles
River Technology, Seoul, Korea), as described previously
[10]. VSMCs between passages four and �ve were used in this
study. Human umbilical vein endothelial cells (HUVECs)
(Invitrogen Life Technology, CA, USA) were grown in
endothelial cell growth medium-2 supplemented with 2%
fetal bovine serum (FBS), 0.04%hydrocortisone, 0.4%human
epidermal growth factor (hEGF)-B, 0.1% vascular endothelial
growth factor (VEGF), 0.1% R3-insulin like growth factor
(IGF)-1, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000, and
0.1% heparin (Lonza, Basel, Switzerland) and synchronized
by serum deprivation (0.1% FBS) for 2 h. HUVECs between
passages 8 and 10 were used in this study. Aer synchro-
nization, VSMCs and HUVECs were treated with DE for
24 h prior to stimulation with platelet-derived growth factor
(PDGF)-BB (R&D Systems, MN, USA) and tumor necrosis
factor (TNF)-𝛼𝛼 (Millipore,MA, USA). PDGF-BB (20 ng/mL)
and TNF-𝛼𝛼 (10 ng/mL) were applied to both VSMCs and
HUVECs for 24 h.
2.3. Cell Proliferation Analysis, Wound Healing Assay, and
Reactive Oxygen Species Assay. Cell proliferation was
assessed using a modi�ed 3-[4,5-dimethyl-2-thiazolyl]-2,5-
diphenyl-2 tetrazolium bromide (MTT) (Sigma-Aldrich Co.)
assay following a standard protocol [11]. Wound healing
assays were performed using 6-well plates. When cells
reached 90% con�uence, synchronized cells were pretreated
with DE (100 𝜇𝜇g/mL) in serum-free medium for 24 h. Aer
24 h of PDGF-BB (20 ng/mL) stimulation, a single wound
was created in the center of the cell monolayers by gentle
removal of the attached cells with a sterile plastic pipette
tip. Aer 24 h of incubation, the cells that migrated into
the wounded area or protruded from the border of the
wound were visualized and photographed under an inverted
microscope.e eﬀect of DE on intracellular reactive oxygen
species (ROS) levels was examined as described previously
[12]. Brie�y, at 24 aer PDGF (20 ng/mL) following DE
(100 𝜇𝜇g/mL) treatment, cells were incubated for 30min at
37∘C with CM-H2DCF-DA (Molecular Probes Inc., OR,
USA).
2.4. Propidium Iodide Staining for Cell Cycle Analysis. At 24
aer PDGF (20 ng/mL) treatment following DE (100 𝜇𝜇g/mL)
pretreatment, cells were harvested and washed with PBS, fol-
lowed by �xation with 70% ethanol overnight at −20∘C. Aer
washing with 3% BSA/PBS twice, the cells were resuspended
in PBS containing 50 𝜇𝜇gmL propidium iodide and 10 𝜇𝜇gmL
RNase A for 30min at room temperature. Samples were
analysed for DNA content by �ow cytometry. e cell-cycle
phases were analysed using CELLQuest soware (Becton
Dickinson, San Jose, CA, USA).
2.5. Immunoblotting. Cell lysateswere subsequently prepared
and subjected to western blot analysis. Membranes were
then immunoblotted with primary antibodies for phosphor-
Akt (Ser473) (Cell Signaling), nonmuscle heavy chain II-
A (Abcam, MA, USA), manganese superoxide dismutase
(MnSOD) (Abcam), lamin A (Santa Cruz, CA, USA), JNK
(Cell Signaling Technologies, MA, USA), p65 (Cell Signaling
Technologies), and hemoxygenase-1 (HO-1) (Santa Cruz).
Peroxidase-conjugated anti-rabbit or anti-mouse antibodies
were used as secondary antibodies (ermo Fisher Scien-
ti�c). Isolation of nuclear fractions was carried out by using a
commercial kit (Cayman Chemical ItemNumber 10009277).
2.6. Rat Model for Carotid Artery Balloon Injury. e in
vivo therapeutic eﬀect of DE on neointimal hyperplasia was
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investigated with a balloon injury animal model as previ-
ously described [13]. Male Sprague-Dawley rats (250–300 g;
ORIENT-Charles River Technology) were separated into
three groups, including vehicle treatment (𝑛𝑛 𝑛 𝑛), DE
(10mg/kg) treatment (𝑛𝑛 𝑛 𝑛), and DE (50mg/kg) treatment
(𝑛𝑛 𝑛 𝑛). DE and vehicle were administered via oral sonde
daily beginning two weeks before until four weeks aer
induction of balloon injury. To evaluate the eﬀect of DE
pretreatment on neointimal hyperplasia, SD rats were clas-
si�ed into three groups in separate studies, including vehicle
treatment (𝑛𝑛 𝑛 𝑛), DE treatment for four weeks aer balloon
injury (𝑛𝑛 𝑛 𝑛), and DE pretreatment for two weeks followed
by DE treatment for four weeks aer balloon injury (𝑛𝑛 𝑛 𝑛).
Vehicle or DE (10mg/kg/d) was administered daily. Four
weeks aer balloon injury, the morphometric analysis of
common carotid arteries was performed by staining with
hematoxylin and eosin. Images of each carotid artery section
were analyzed by computerized morphometry (Scion Image
Soware), and luminal, intimal, and medial areas were
then calculated for each arterial cross section. Neointimal
formation was expressed as a percent computed as follows:
[intima/(media + intima)] × 100 (%).
2.7. RatModel for Tail Veinrombosis. To evaluate the eﬀect
of DE on thrombosis formation, thrombosis was induced via
the tail veins of male SD rats (250–300 g) (Orient-Charles
River Technology) classi�ed into three groups, namely, vehi-
cle (normal saline, 𝑛𝑛 𝑛 𝑛) or DE pretreatment for two weeks
before the induction of tail vein thrombosis (10, 50mg/kg,
each 𝑛𝑛 𝑛 𝑛). DE was administered daily through oral
gavage. Bleeding time was checked aer pretreatment for two
weeks as described previously [14]. Tail vein thrombosis was
achieved with a modi�ed Beckmeier�s model as previously
described [15].e length of the thrombosis was evaluated 6,
24, 48, 96, and 168 hours aer 𝜅𝜅-carrageenan injection. Hep-
arin (200U (mL/Kg)−1) was injected i.p. as a positive control
for antithrombotic agents 10 minutes aer 𝜅𝜅-carrageenan
administration.
2.8. Inhibitory Action on Rat Platelet Aggregation. Platelet
aggregation was evaluated using an impedance aggregometer
(Chronologmodel 700, Chronolog Corporation, Havertown,
PA, USA) aer ex vivo and in vivo treatment of DE. For
ex vivo studies, whole blood (9mL) was obtained from
male SD rats (Orient-Charles River Technology) weighing
between 250–300 g. Whole blood was collected in plastic
syringes containing heparin (1.5%) (JW Pharmaceuticals,
Seoul, Korea) to avoid premature aggregation. Single-use
cuvettes containing a silicon-coated stirrer (Chronolog Cor-
poration) (1200 rpm) were �lled with 500𝜇𝜇L physiological
saline and 500 𝜇𝜇L prepared whole blood. Aer incubating
for 15 minutes at 37∘C, the aggregation of platelets in whole
blood was initiated by adding ADP (20 𝜇𝜇M) (Sigma-Aldrich
Co., MO, USA) as a stimulating agonist. Pretreatment of
DE (0.2mg/mL, 2.5mg/mL, and 5.0mg/mL) was performed
10 minutes prior to the initiation of aggregation. For in
vivo studies, male SD rats (Orient-Charles River Technology)
weighing between 200 to 250 g were classi�ed into three
groups, namely, DE (10mg/kg and 50mg/kg) and vehicle
treatments. In the DE treatment group (each group 𝑛𝑛 𝑛 𝑛),
DE was administered daily via oral sonde for two weeks.
Aer treatment with DE or normal saline, whole blood was
obtained and analyzed with an impedance aggregometer.
2.9. Rabbit Iliac Artery Stent Model. e therapeutic eﬀect
of DE on thrombosis was investigated with an iliac artery
stent insertion rabbit model. Brie�y, the iliac artery stent
was inserted as previously described [16]. Male New Zealand
white rabbits (𝑛𝑛 𝑛 𝑛) (Orient-Charles River Technology)
weighing 3.5 to 4.0 kgwere classi�ed into two groups, namely,
the normal saline group (𝑛𝑛 𝑛 1) and DE group (𝑛𝑛 𝑛 𝑛).
Each agent was injected subcutaneously twice a day from
two weeks before to four weeks aer the procedure. DE was
dissolved in normal saline containing 1%DMSOand injected
with a single 20mg/kg dose. Aspirin was administered
orally once a day at a dose of 100mg/animal to all rabbits,
beginning two days before the procedure and continued until
sacri�ce. Fourweeks aer the procedure, stented arterieswere
evaluated with intravascular optical coherence tomography
(OCT). Animals were subse�uently sacri�ced and the stented
segments of both iliac arteries were harvested. Using OCT
and harvested arteries, the size of in-stent restenosis was
calculated.
2.10. Statistical Analyses. Data were analyzed using Mann-
Whitney tests. All statistical analyses were performed using
SPSS (ver. 13.0 for Windows; SPSS, Inc., Chicago, IL, USA).
All statistical tests were two-tailed, and 𝑃𝑃 values <0.05 were
considered signi�cant.
3. Results
3.1. Danshen Extract Contains anAbundance ofWater-Soluble
Components. Twelve compounds were utilized as reference
agents in UPLC-UV [17]. ey included salvianic acid
(danshensu), dihydroxybenzoic acid (protocatechuic acid),
dihydroxybenzaldehyde (protocatechuic aldehyde), caﬀeic
acid, rosmarinic acid, lithospermic acid, salvianolic acid B,
salvianolic acid A, dihydrotanshinone I, cryptotanshinone,
tanshinone I, and tanshinone IIA. Most of the compounds
in DE were water soluble, whereas the number of solely
liposoluble compounds was minimal (Table 1).
3.2. Danshen Extract Has Antioxidant, Antimigratory and
Antiproliferative Eﬀects on PDGF-BB Stimulated VSMCs. e
eﬀects of DE on ROS generation,migration, and proliferation
of VSMCswere evaluated by PDGF-BB induction. According
to the CM-H𝑛DCF-DA emission results from FACS, DEmost
signi�cantly decreased the amount of ROS at a concentration
of 100 𝜇𝜇g/mL (Figure 1(a)). Further in vitro studies were
conducted with a 100 𝜇𝜇g/mL concentration of DE, the levels
of which increased MnSOD and HO-1 expression. Both are
importantmolecules for the inhibition ofVSMCproliferation
and ROS production. e expression of HO-1 was increased
by DE even aer PDGF-BB treatment. On MnSOD, DE
treatment prevented the decreased expression induced by
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T 1: Ultra performance liquid chromatography—ultraviolet
assay of Danshen extracts.
No. Reference compound Amount in DE1mg (𝜇𝜇g/mg) Solubility
1 Salvianolic acid A(danshensuan A) 22.959 Water
2 Dihydroxybenzoic acid(Protocatechuic acid) 0.41 Water
3 Dihydroxybenzaldehyde(Protocatechuic aldehyde) 19.37 Water
4 Caﬀeic acid 4.34 Water
5 Rosmarinic acid 87.558 Water
6 Lithospermic acid 30.298 Water
7 Salvianolic acid B 133.932 Water
8 Salvianolic acid A 53.763 Water
9 Dihydrotanshinone I <0.205 Lipid
10 Cryptotanshinone <0.273 Lipid
11 Tanshinone I <0.236 Lipid
12 Tanshinone IIA <0.661 Lipid
PDGF-BB (Figure 1(b)). To evaluate changes in PDGF
signaling aer DE treatment, the expression of PI3K/Akt was
analyzed. Although PDGF-BB (20 ng/mL, 24 h) stimulated
the phosphorylation of Akt, this eﬀect was blocked by DE
treatment with a dose of 100 𝜇𝜇g/mL (Figure 1(c)).
According to migration studies with VSMCs, PDGF
(20 ng/mL, 24 h) treatment resulted in wound-induced
migration (Figure 1(d)). However, DE treatment signi�cantly
prevented PDGF inducedwoundmigration. ForMTT assays,
quiescent cells were treated with DE (100 𝜇𝜇g/mL for 24 h) in
the absence of PDGF-BB, and then stimulatedwith PDGF-BB
(20 ng/mL, 24 h). Proliferation ofVSMCs treatedwith PDGF-
BBwas 53% higher compared to that in PDGF-BB (−) control
cells. DE inhibited PDGF-BB-induced VSMC proliferation
in a dose-dependent manner, up to 65.7% inhibition at
100 𝜇𝜇g/mL of DE (Figure 1(e)). According to the cell cycle
analysis, DE blocked the induction of S-phase entry, which
normally occurs in PDGF-stimulated VSMCs (Figure 1(f)).
3.3. Danshen Extract Exerts Anti-In�ammatory and Anti-
apoptotic Eﬀects on HUVECs. To determine the eﬀects of DE
on endothelial cells, HUVECs with or without DE pretreat-
ment for 24 h were incubated with TNF-𝛼𝛼 (10 ng/mL) for 24
hours. TNF-𝛼𝛼 alone increased the expression of VCAM-1 in
HUVECs, whereas DE pretreatment signi�cantly inhibited
TNF-𝛼𝛼 induced VCAM-1 expression (Figure 2(a)).e eﬀect
of DE on VCAM-1 expression in the HUVECs correlated
with that of balloon injured rat arteries. Although endothe-
lium exhibited a signi�cant increase in VCAM-1 expression
aer balloon injury, the expression of VCAM-1 in those
of rats who had been given DE was signi�cantly decreased
(Figure 2(a)).
To determine the eﬀect of DE on upstream signaling of
VCAM-1, changes to the mitogen-activated protein kinase
(MAPK) and nuclear factor (NF)-𝜅𝜅B pathways were evalu-
ated. Brie�y, cells were exposed to TNF-𝛼𝛼 (100 ng/mL) for
15min with or without pretreatment with DE (100 𝜇𝜇g/mL)
for 24 h. With respect to TNF-𝛼𝛼-induced MAPK activation,
DE signi�cantly inhibited the TNF-𝛼𝛼-induced phosphory-
lation of JNK (Figure 2(b)). Furthermore, DE blocked the
NF-𝜅𝜅B pathway, which was con�rmed by analyzing nuclear
protein levels of NF-𝜅𝜅B p65 (Figure 2(c)). Following TNF-
𝛼𝛼 treatment on HUVECs, levels of cytosolic NF-𝜅𝜅B were
decreased, whereas increased nuclear expression was noted.
However, DE apparently inhibited the increase of NF-𝜅𝜅B
p65 at nucleus with minimal change of cytosolic expression.
In brief, DE inhibited TNF-𝛼𝛼-activated MAPK and NF-𝜅𝜅B
signaling pathways in endothelial cells, which are known
markers involved in the expression of VCAM-1. In addition,
DE increased the expression of HO-1 in HUVECs, similar to
VSMCs (Figure 2(d)).
3.4. Danshen Extract Inhibits Balloon Injury-Induced Neoin-
timal Hyperplasia. Balloon injury-stimulated neointimal
hyperplasia in the carotid artery of SD rats was explicitly
compared to sham-operated rats. With respect to the dose of
DE, the observed eﬀects were signi�cantly prevented by both
doses ofDE treatment, compared to the normal saline-treated
group (58% and 37% in the DE 10mg/kg and DE 50mg/kg
treated groups, respectively, both 𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃) (Figures 3(a)
and 3(b)). In aspect of the signi�cance in DE pretreat-
ment, both methods of DE treatment decreased neointimal
hyperplasia to 42%, compared to the vehicle-treated group
(55% and 42% in the DE 10mg/kg only aer the procedure,
and DE 10mg/kg both before and aer procedure-treated
groups, respectively, both 𝑃𝑃 < 𝑃𝑃𝑃𝑃𝑃) (Figure 3(c)). Although
there was not statistically signi�cance, pretreatment with
DE showed a more intense inhibitory eﬀect on neointimal
hyperplasia compared to the DE treatment group without
pretreatment aer the procedure (Figure 3(c)).
3.5. Danshen Extract Serves As a Bloodinner In Vivo and Ex
Vivo. DE treatment for two weeks resulted in a signi�cantly
prolonged bleeding time (𝑃𝑃 < 𝑃𝑃𝑃𝑃) (Figure 4(a)). For
induction of thrombosis, Beckmeier�s modi�ed model was
utilized, speci�cally. Rats pretreated with or without DE were
observed over a period of seven days aer 𝜅𝜅-carrageenan
injection, analyzing tail length and color. During the �rst 2 to
3 h aer 𝜅𝜅-carrageenan injection, the tail swelled and turned
red. Next, the tail changed to an auburn color around 6 h aer
𝜅𝜅-carrageenan injection. Finally, 96 h aer 𝜅𝜅-carrageenan
injection, the injured tails of the DE pretreatment group had
recovered signi�cantly compared to the vehicle pretreatment
group (𝑃𝑃 < 𝑃𝑃𝑃𝑃). With respect to the formation of tail vein
thrombosis, DE pretreatment produced the similar eﬀect as
heparin pretreatment (Figures 4(b) and 4(c)).
To evaluate the eﬀect of DE on platelet activation,
DE was administered using both in vivo and ex vivo
models. In both models, DE inhibited the activation of
platelets in a dose-dependent manner (Figures 4(d) and
4(e)). Interestingly, according to the in vivo study results, DE
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F 1: e antioxidant, antimigratory, and antiproliferative eﬀects of Danshen extract on PDGF-BB-treated vascular smooth muscle
cells. Platelet-derived growth factor (PDGF)-BB (20 ng/mL) was treated for 24 h aer Danshen extracts (DE) treatment at each concentration
for 24 h. (a) Fluorescence activated cell sorting for PDGF-BB-induced intracellular reactive oxygen species in vascular smooth muscle cells
(VSMCs). (b) Western blotting for manganese superoxide dismutase and hemoxygenase-1. DE (100 𝜇𝜇g/mL) treated for 24 h before PDGF
treatment. (c) Western blotting for proteins on Akt signaling pathway aer treatment DE (100 𝜇𝜇g/mL) for 24 h. (d) e wound-healing
experiment with or without DE (100 𝜇𝜇g/mL, 24 h). (e) Proliferation assessed by the MTT cell proliferation assay. Relative proliferation
activities were expressed using untreated control cells as a standard. Results are expressed as the mean ± standard error; ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 versus
vehicle treatment aer PDGF-BB induction. (f) e eﬀects of DE on cell cycle progression. DE: Danshen extract.
treatment induced early recovery from platelet aggregation,
which was con�rmed with an impedance aggregometer
(Figure 4(e)).
3.6. Danshen Extract Prevented In-Stent Restenosis. Four
weeks aer stent insertion, the extent of in-stent resteno-
sis was assessed in histological sections of stented rabbit
iliac arteries. Compared with the levels in the control
group treated with aspirin during procedure, DE treatment
combined with aspirin markedly attenuated the formation of
in-stent restenosis (Figure 5(a)). Furthermore, OCT technol-
ogy demonstrated that the area of restenosis in theDE-treated
groupwas decreased to 30% comparedwith the control group
(Figures 5(b) and 5(c)). e size of restenosis was analyzed
at six points in each stented artery. In addition, minimal
numbers of both red and white thrombi were found in
the DE-treated group, whereas these cells were ubiquitously
present in control cells.
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F 2: Anti-in�ammatory and antiapoptotic eﬀects of Danshen extract on human umbilical vein endothelial cells. (a) Western blotting
(le panel) and immunohistochemical staining (right panel) forVCAM-1.Humanumbilical vein endothelial cells (HUVECs)were pretreated
with Danshen extract (DE) (100 𝜇𝜇g/mL) 24 h prior to exposure with TNF-𝛼𝛼 (10 ng/mL) for 24 h. Representative immunohistologic sections
(200X) of VCAM-1 in balloon-injured rat carotid arteries were shown. (b)-(c) Western blotting for phosphorylated JNK and NF-𝜅𝜅B p65.
HUVECs were treated with TNF-𝛼𝛼 (100 ng/mL) for 15m with or without pretreatment with DE (100 𝜇𝜇g/mL) for 24 h. (d) Western blotting
for hemoxygenase-1 in both HUVECs with or without treatment of TNF-𝛼𝛼 (100 ng/mL) for 15min. DE: Danshen extract.
4. Discussion
Atherosclerosis is amultifactorial disease associatedwith var-
ious risk factors. e cellular pathogenesis of atherosclerosis
is characterized by endothelial dysfunction, VSMC prolif-
eration, and platelet aggregation. Importantly, these three
factors play critical roles in the development of atheroscle-
rosis and in the progress of cardiovascular disease [18, 19].
e mechanisms of aspirin and clopidogrel, which are two
common medicines used in the treatment of atheroscle-
rotic cardiovascular diseases, have various pathways aﬀecting
the vascular endothelium, VSMC, and platelets. However,
these drugs have the potential for serious adverse reactions
including hemorrhage and hematologic adverse reactions
[20]. Furthermore, issues regarding resistance to aspirin and
clopidogrel have led to the need for the development of newer
agents.
Recently, several studies have reported that natural prod-
ucts such as herbal medicines have therapeutic eﬀects on car-
diovascular diseases. However, these treatments face limited
acceptance by the clinical opinion makers due to the lack
of de�ned mechanisms involving their antiatherosclerotic
eﬀects. In this study we used three diﬀerent animal models
aer analyzing the eﬀects andmechanisms of DE in vitrowith
endothelial cells, VSMCs, and platelets.
e proliferation and migration of VSMCs to the intima
leads to neointimal hyperplasia and this process is triggered
by multiple factors. Cytokines and growth factors such as
PDGF, which is produced by platelets, VSMCs, and endothe-
lial cells in the injured vascular wall involved in this process.
Abnormal proliferation of VSMCs is thought to play an
important role in the pathogenesis of atherosclerosis and
restenosis aer stent insertion. Recent evidence indicates that
increased intracellular level of ROS is one of the main mech-
anisms in proliferation and migration of VSMCs [21, 22].
MnSOD and HO-1 have the roles in the atherogenic eﬀect of
ROS.MnSOD is located in themitochondrialmatrix and pro-
tects the mitochondria against oxidative stress [23]. Together
with MnSOD, HO-1 expression also attenuates PDGF-
induced VSMC proliferation and ROS production [24].
In this study, treatment with DE led to decreased ROS
production, followed by an increased abundance of MnSOD
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F 3: Eﬀect of Danshen extract on neointimal formation aer carotid artery balloon injury in rats. (a)-(b) Rats were orally administered
one of two diﬀerent concentrations ofDanshen extract (DE) (10 and 50mg/kg/d, both 𝑛𝑛 𝑛 𝑛; represented asDE 10 andDE 50, resp.,) or vehicle
(𝑛𝑛 𝑛 𝑛) every day from 2 weeks before and to four weeks aer balloon injury. (a) Representative histologic sections of neointimal formation.
Le, vehicle treatment; Middle, DE (10mg/kg/d) treatment; Right, DE (50mg/kg/d) treatment. (b) Neointimal formation aer balloon injury
according to the doses of treated DE. (c) Neointimal formation aer balloon injury according to the existence of DE pretreatment. To evaluate
the eﬀect of DE pretreatment on neointimal hyperplasia, rats were subjected to DE treatment (10mg/kg/d) for one of two periods of time:
four weeks aer injury, 𝑛𝑛 𝑛 𝑛 (Post-DE 10); two weeks before injury until 4 weeks aer injury, 𝑛𝑛 𝑛 𝑛 (Pre-DE10 + Post-DE10). e
neointimal formation was calculated by [intima/(media + intima)] × 100 (%).e bar indicates the standard error. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 for the indicated
comparisons. DE: Danshen extract.
and HO-1 proteins. In aspect of VSMCs migration, PI3K-
Akt pathway is important to activate the NADH oxidase,
leading to ROS production. It is well known that PI3K/Akt
is the main PDGF signaling pathway and that this pathway
is linked to numerous cellular processes, including both
proliferation and migration [25]. DE inhibited phosphory-
lation of Akt, resulting in the accompanying inhibition of
VSMC migration. Furthermore, wound-induced migration
was signi�cantly prevented by DE. Brie�y, DE inhibited
proliferation and migration, decreased the production of
ROS, and inhibited the PI3K-Akt pathway in VSMCs.
TNF-𝛼𝛼, one of the major in�ammatory cytokines,
mediates systemic in�ammation and immune responses
by enhancing the expression of adhesion molecules and
the secretion of in�ammatory mediators in the vascular
endothelium [26]. Accumulating evidence suggests that the
induction of VCAM-1 or ICAM-1 by TNF-𝛼𝛼 in endothelium
is mediated by the activation of MAPK and transcription
factors such as NF-𝜅𝜅B [13], leading to the pathogenesis
of atherosclerosis. Although TNF-𝛼𝛼 alone signi�cantly
increased the level of VCAM-1 expression, DE pretreatment
clearly inhibited VCAM-1 expression in HUVECs. In the
present study, the change of VCAM-1 expression was linked
to eﬀect of TNF-𝛼𝛼 in HUVECs as well as balloon-injured
endothelium of rats aer DE treatment. With respect to
the upstream molecules of VACM-1, MAPKs, which are a
group of highly conserved serine/threonine kinases includ-
ing JNK, participate in the vessel in�ammatory reactions
via integration of stimuli acting on cells, production of
in�ammatory mediators via the phosphorylation of down-
stream kinases, and the activation of transcription factors
[27]. DE signi�cantly inhibited TNF-𝛼𝛼-induced phosphory-
lation of JNK in HUVECs. In this study, cytosolic NF-𝜅𝜅B was
decreased following increased expression ofNF-𝜅𝜅Bprotein in
the nucleus aer TNF-𝛼𝛼 treatment. However, treatment with
DE apparently inhibited the NF-𝜅𝜅B pathway by preventing
translocation. us, our data suggested that DE inhibited
TNF-𝛼𝛼-induced activation of the JNK and NF-𝜅𝜅B signaling
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F 4: Blood thinning eﬀect of Danshen extract. (a)–(c) Danshen extract (DE) pretreated at a dose of 10mg/kg daily for 2 weeks via oral
sonde (𝑛𝑛 𝑛 𝑛 in each group). (a) Bleeding time in response to treatment with DE. (b) Gross changes in the tail vein 96 h aer 𝜅𝜅-carrageenan
injection.ewhite bar indicates the position 13 cm from the tail tip.e black bar indicates the reference length. (c)e length of thrombosis
aer 𝜅𝜅-carrageenan injection. �n the tail vein thrombosis rat model� DE treatment signi�cantly inhibited thrombosis formation at 96 h aer
𝜅𝜅-carrageenan injection. (d) Platelet aggregation aer DE treatment in ex vivo condition. e impedance aggregometer revealed that DE
prevented platelet aggregation in a dose-dependent manner ex vivo. (e) Platelet aggregation aer DE treatment in in vivo condition. Whole
blood was sampled aer DE pretreatment. Danshen extract (DE) administered at a dose of 10mg/kg/d (DE 10) or 50mg/kg/d (DE 50) for 2
weeks via oral sonde (𝑛𝑛 𝑛 𝑛 in each group). e platelet aggregation that was induced by ADP recovered more quickly with increasing doses
of DE used in pretreatment. Graph of impedance aggregometer represented the mean value of each group. Results are expressed as the mean
± standard error. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 versus vehicle treatment. DE: Danshen extract.
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F 5: Eﬀects of Danshen extract on in-stent restenosis. Rabbits were subcutaneously administered Danshen extract (DE; 20mg/kg) twice
a day from two weeks before to four weeks aer the stent insertion. (a) Representative cross sections of stented iliac arteries in DE-treated and
vehicle-treated rabbits 4 weeks aer stent insertion. Sections were stained with hematoxylin and eosin; scale bar: 500 𝜇𝜇m. (b) Intravascular
imaging for each iliac artery via intravascular optical coherence tomography (OCT). DE-treated rabbits showed signi�cantly decreased in-
stent restenosis. (c) Imaging analysis of in-stent restenosis, obtained fromOCT. Results are expressed as the mean ± standard error. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃
for the indicated comparisons. DE: Danshen extract.
pathways, which might contribute to the suppression of
VCAM-1 in the endothelium.
Together with VSMCs and endothelial cells, thrombosis
formation induced by platelets plays a major role in the
development of atherosclerosis. In this study, we examined
the antiplatelet and antithrombotic eﬀects of DE. Platelet
aggregation is a complex process that is mediated primarily
through platelet adhesion at the injured site with the acti-
vation of endogenous agonists such as ADP, collagenase,
and thrombin. ese agonists stimulate platelet aggregation,
resulting in thrombus formation through receptors on the
platelet membrane [28]. In commercially popular agents,
aspirin targets for the ADP. In this study, DE inhibited the
ADP-induced aggregation of platelets in both in vitro and
in vivo conditions. In the in vivo study with the impedance
aggregometer, DE blocked the secondary activation of
platelet aggregation in a manner similar to the eﬀects of
aspirin. Further study using multiple agonists for platelet
activation could be helpful in understanding the antiplatelet
eﬀects of DE. e eﬀect of DE on thrombus formation was
studied using the rat model of tail vein thrombosis, a model
that can be used to evaluate the eﬀects of antithrombotic and
thrombolytic agents [29]. Heparin treatment, which was used
as a positive control agent, had similar eﬀects on tail vein
thrombosis as reported previously [29]. e antithrombotic
eﬀects of DE were similar to those of heparin. Furthermore,
antithrombotic eﬀect of DE was recon�rmed in rabbit iliac
artery stent model.
�ith results con�rmed in both in vitro and in vivo rat
models, the antiatherogenic eﬀects of DE were analyzed in
a rabbit animal model. e in-stent restenosis animal model
is important for understanding thrombosis formation and
vascular biology [30]. As seen with the rat models, DE
had dramatic eﬀects on the prevention of instent restenosis
including vascular proliferation and thrombus formation in
a rabbit model.
e progression of atherosclerosis consists of multiple
processes including, oxidative stress, migration and prolifer-
ation of VSMC, in�ammation and dysfunction of endothelial
cells, and thrombosis formation. In this study, DE showed
multiple therapeutic functions on each pathophysiology of
atherosclerosis. Multifunctional roles of DE on pathogenesis
of atherosclerosis could be explained by the multiple compo-
nents constituting the extracts. e need for development of
natural compounds as therapeutics might be explained with
this reason. However, further studies should be advanced
to evaluate the key mechanism of DE on atherosclerosis.
e key mechanism could present the speci�ed indication as
therapeutics.
Several studies demonstrated the eﬀect of each DE
component on atherosclerosis, suggesting the possible
mechanisms. Until now, most studies evaluating the
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antiatherosclerotic eﬀects of Danshen used lipid-soluble
components and focused on it. In terms of the extract’s
water-soluble components, rosmarinic acid, lithospermic
acid, ursolic acid, and salvianolic acid B have been reported
to have antiatherogenic or antithrombotic eﬀects [31, 32,
33]. Furthermore, we reported that protocatechuic aldehyde
which is one of themain water-soluble components dissolved
in DE inhibited migration and proliferation of VSMCs
and intravascular thrombosis [34]. In aspect of molecular
mechanisms, most of them had inhibitory actions on MMP-
2/9, VACM-1, ICAM-1, and NF-𝜅𝜅B. However, the protective
action of the each component had been achieved with the
relative high concentration compared with DE used in this
study. DE used in this study was not comprised of a single
component but rather a mixture of the components of the
extracts. is included mostly water-soluble agents because
of the method of extraction. DE used in this study showed
more stronger eﬀects compared with previously reported
results for either single components or combinations of
dual components at similar molecular concentrations [35].
is means that DE in this study had synergistic eﬀects
or at least additional eﬀects on preventing atherosclerosis
compared with that from each single component of danshen.
e higher eﬀects with relative lower concentration of each
component are important to make it useful in developing
new therapeutics. e results of this study suggest not
only the medical usefulness of DE but also the need for
evaluation of underlying mechanism on interaction between
each component.
In conclusion, we have demonstrated that DE, with its
prominent water-soluble components, exerts a protective
eﬀect against atherosclerosis by inhibiting multiple pathways
associated with VSMCs, endothelial cells, and platelets. e
antiatherogenic eﬀects of DE were con�rmed both in vitro
and in vivo, including in rat and rabbit models. ese results
support the possibility of implementing water soluble DE as a
therapeutic agent in the treatment of cardiovascular diseases.
Further studies on the individual water-soluble components
of DE are needed in order to evaluate the therapeutic eﬀects
of DE on cardiovascular diseases.
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